Olumiant (Baricitinib)

Save over 80% with brand Olumiant from Europe and 90% buying the generic version of Olumiant from Insulinhub.

For more info on generic medicines made by Dr. Reddy's click here

Will ship in English or Non-english packaging (depending on availability - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

Medicine brands include Olumiant and Unamity - all exactly the same medicine from the same factory:

Manufacturer for European prduct: Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain.

Olumiant contains baricitinib, which is taken by adults to treat moderate to severe active rheumatoid arthritis who have inadequate response or intolerance to other anti-rheumatic medicines.  Olumiant reduces the enzymatic activity of Janus kinase which is involved in the inflammatory process.  Olumiant works in the body to reduce stiffness, swelling, pain, and tiredness.  Olumiant also slows the damage to bone cartilage in the joints.

Olumiant is usually taken at a daily dose of 4mg.  Some patients will be taking the lower dose 2mg per day. Olumiant is used alone or along with methotrexate under the direction of a doctor which specializes in rheumatoid arthritis.

Information about Olumiant (Baricitinib)

Olumiant is a brand name for baricitinib, an oral Janus kinase (JAK) inhibitor used to treat inflammatory conditions. It works by inhibiting JAK enzymes, which play a key role in the immune system’s signaling pathways. By blocking these enzymes, baricitinib helps reduce inflammation and immune responses. Olumiant is primarily used for autoimmune diseases like rheumatoid arthritis and has also been investigated for use in other conditions like COVID-19.

Product Highlights

• Olumiant is approved for the treatment of moderate to severe rheumatoid arthritis in adults who have not responded adequately to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
• Baricitinib is authorized for emergency use in hospitalized adults and pediatric patients with COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), in combination with other medications.
• Baricitinib is under investigation for the treatment of other conditions involving inflammation, such as psoriatic arthritis and atopic dermatitis.

Key Ingredient

• Baricitinib

Key Benefits

• By targeting JAK enzymes, baricitinib effectively reduces inflammation, which helps manage autoimmune and inflammatory conditions.
• In rheumatoid arthritis, it can help reduce joint pain, swelling, and stiffness, improving the ability to move and perform daily tasks.
• Unlike biologic therapies, Olumiant is taken orally, which eliminates the need for injections or infusions.
• Many patients experience symptom relief relatively quickly, often within 2-4 weeks.
• Baricitinib has shown potential in altering the progression of rheumatoid arthritis, offering long-term benefits for disease management.

Direction of Use

• Olumiant is taken orally as a tablet, typically once or twice daily, depending on the prescribed dosage.
• The usual starting dose for rheumatoid arthritis is 2 mg once daily, but this can be adjusted based on the patient's response and tolerance.
• For COVID-19, the dosing schedule may vary, typically based on the patient's clinical condition and in conjunction with other treatments (e.g., corticosteroids).

With or without food: It can be taken with or without food, but it's important to follow the dosing instructions provided by a healthcare provider.

Safety Concerns

• Baricitinib can weaken the immune system, making patients more susceptible to infections such as tuberculosis, bacterial, fungal, or viral infections.
• Baricitinib may increase the risk of blood clots, deep vein thrombosis (DVT), pulmonary embolism (PE), or other clotting issues.
• Baricitinib may cause liver damage, so liver function tests are recommended during treatment.
• It may lead to higher cholesterol and lipid levels, which should be monitored regularly.
• As with other immunosuppressive drugs, there is a potential increased risk of certain types of cancer, such as lymphoma.
• Some patients may experience abdominal discomfort, nausea, or other gastrointestinal side effects.

Avoid Olumiant (Baricitinib) If

• You have a known allergy to baricitinib or any other components of the medication.
• You have a history of serious infections, such as tuberculosis, HIV, or Hepatitis B/C, as baricitinib can increase the risk of infection.
• You are pregnant or planning to become pregnant, as baricitinib may harm the fetus. It is classified as Pregnancy Category C (risk cannot be ruled out).
• You are breastfeeding, as it is unknown whether baricitinib passes into breast milk and could potentially harm the infant.
• You have a history of blood clots or cardiovascular disease, as baricitinib may increase the risk of clotting events.
• You have liver disease (severe liver impairment) without dose adjustment, as the drug may exacerbate liver conditions.
• You are taking strong immunosuppressive medications (e.g., other JAK inhibitors, biologic DMARDs) without a doctor’s supervision, as the combination can increase the risk of serious side effects.